Please assess the completion status of the following clinical trial:

Trial Title: Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or non-pregnant, non-lactating female aged ≥40.~* Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years~* Patients with a clinical diagnosis of COPD according to GOLD guidelines 2013, with a post-bronchodilator FEV1 \<80%, and FEV1/FVC \< 70% at Screening Visits~* Symptomatic patients with a COPD assessment test (CAT) ≥10 at Screening and Randomisation Visits~* Patient must be able to perform repeatable pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria at Screening Visits~* Patients eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained~Exclusion Criteria:~* History or current diagnosis of asthma~* Development of a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if hospitalisation was required) before the Screening Visit or during the run-in period~* Clinically significant respiratory conditions~* Type I or uncontrolled Type II diabetes, uncontrolled hypo- or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension~* Patients who, in the investigator's opinion, may need to start a pulmonary rehabilitation programme during the study and/or patients who started/finished it within 3 months prior to Screening Visit~* Use of long-term oxygen therapy (≥15 hours/day)~* Patients treated on daily basis with triple therapy (LABA+LAMA+ICS) within 4 weeks prior to the Screening Visit~* Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers~* Clinically significant cardiovascular conditions~* Patient with clinically relevant abnormalities in the results of the clinical laboratory tests, ECG parameters or in the physical examination at the Screening Visit~* Patient with a history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm)~* Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy~* Patient with known non-controlled history of infection with human immunodeficiency virus (HIV) and/or active hepatitis~* History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer~* Patient with any other serious or uncontrolled physical or mental dysfunction~* Patient with a history (within 2 years prior to Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment~* Patient unlikely to be cooperative or that can't comply with the study procedures~* Patient treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening Visit~* Patient who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication~* Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium Bromide / Formoterol Fumarate (Type: EXPERIMENTAL): Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
- Salmeterol / Fluticasone propionate (Type: ACTIVE_COMPARATOR): Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).